PEI Drug Programs. Issue February 20, 2009
|
|
- Franklin Myron Cook
- 5 years ago
- Views:
Transcription
1 PEI Drug Programs Formulary Update Issue February 20, 2009 New medications for the treatment of cancer, chronic obstructive pulmonary disease (COPD), osteoporosis, and HIV/AIDS have been approved for coverage by the PEI Drug Programs, effective March 1, Coverage of all of the new medications have been approved based on recommendations made by the Atlantic Expert Advisory Committee, the Canadian Expert Drug Advisory Committee, or the Joint Oncology Drug Review. The new medications will be covered through a combination of the Family Health Benefit, Financial Assistance, High Cost Drugs, HIV/AIDS, Nursing Home, and Seniors Programs. Most of the new medications will require the patient s medical condition to meet established clinical criteria before coverage will be approved. Physicians must submit a completed Special Authorization (Exceptional Drug) form to the Drug Programs office before coverage will be considered. Medications covered through the High Cost Drugs Program will also require patients or their care givers to complete a High Cost Drugs Program application and to submit it along with income verification information to the Drug Programs office. This information will be used to calculate the patient s share of the prescription cost. Copies of the application form may be obtained by contacting the Drug Programs office or online at: High Cost Cancer Medications The following cancer medications will be covered through the High Cost Drugs Program to patients who meet the established clinical criteria. A completed Special Authorization form must be received by the Drug Programs office before coverage will be considered. Patients must also submit a completed High Cost Drugs Program application and income verification information to the Drug Programs Office. Dasatinib (Sprycel) 20 mg, 50 mg, and 70 mg Tablets For use as a single agent for the treatment of adults with chronic, accelerated or blast phase chronic myelogenous leukemia (CML) and Philadelphia chromosome acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy including imatinib. Erlotinib (Tarceva) 25 mg, 100 mg, and 150 mg Tablets For use as monotherapy for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen and whose EGFR expression status is positive or unknown. Fludarabine (Fludara) 10 mg Tablets For the treatment of chronic lymphocytic leukemia (CLL) in patients with an ECOG performance status of 0 to 2 when the patient has failed to respond to, or relapsed during/ after previous therapy with an alkylating agent and intravenous administration is not desirable. PEI Drug Programs Update - Issue Page 1
2 Sorafenib (Nexavar) 200 mg Tablets 1. For use as a single agent second line treatment in patients with documented evidence of histologically confirmed advanced or metastatic clear cell renal cell carcinoma, considered to be intermediate or low risk (according to Memorial Sloan-Kettering (MSKCC) prognostic score, see below), have an ECOG performance status of 0 or 1 and progressed after prior cytokine therapy (or intolerance) within the previous 8 months. In any one patient all of the following conditions must be met: Sorafenib may be a second line option only after cytokine therapy. Sorafenib may not be used after another tyrosine kinase inhibitor (i.e., sunitinib) as sequential therapy. In the event of severe toxicity within the first 8 weeks of therapy, a switch to another tyrosine kinase inhibitor (i.e., sunitinib) may be allowed. 2. For use in patients with Child-Pugh Class A advanced hepatocellular carcinoma, who have progressed on trans-arterial chemoembolization (TACE) or are not suitable for the TACE procedure, and have an ECOG performance status of 0 to 2. Renewal of coverage requires no further progression of the patient s disease as evidenced by radiological or scan results. Copies of the results must accompany the Special Authorization. Sunitinib (Sutent) 12.5 mg, 25 mg, and 50 mg Capsules 1. For use as a single agent first line treatment in patients with documented evidence of histologically confirmed advanced or metastatic clear cell renal cell carcinoma who have an ECOG performance status of 0 or 1. In any one patient all of the following conditions must be met: Sunitinib may be a first line option. Sunitinib may not be used after another tyrosine kinase inhibitor (i.e., sorafenib) as sequential therapy. In the event of severe toxicity within the first 8 weeks of therapy, a switch to another tyrosine kinase inhibitor (i.e., sorafenib) may be allowed. 2. For use as a single agent for the treatment of advanced gastrointestinal stromal tumor (GIST) patients after failure of imatinib due to intolerance or resistance. Adjunctive Cancer Medications Coverage of the following adjunctive cancer medications will be provided to patients who meet established clinical criteria and who are eligible for coverage through the Family Health Benefit, Financial Assistance, Seniors, and Nursing Home Programs. A completed Special Authorization form must be received by the Drug Programs office before coverage will be considered. Patients will be required to pay the normal prescription copays for these programs. Aprepitant (Emend) 80 mg and 125 mg Capsules For use in combination with a 5-HT antagonist and dexamethasone in adult cancer patients treated with 2 chemotherapy that includes cisplatin as a single day therapy greater than or equal to ( ) 70 mg/m to prevent acute and delayed nausea and vomiting. The 5-HT antagonist should only be used on the first day of cisplatin therapy with aprepitant continuing on Days 2 and 3. The dose of dexamethasone may be adjusted due to the increased levels of dexamethasone when combined with aprepitant. Dronabinol (Marinol) 2.5 mg and 5 mg Capsules For the treatment of severe nausea and vomiting associated with cancer chemotherapy in patients who have not been well controlled by standard stepwise antiemetic therapy. PEI Drug Programs Update - Issue Page 2
3 Thyrotropin (Thyrogen) 0.9 mg/ml Injection Solution For use as a single agent in patients who have documented evidence of thyroid cancer, who have undergone appropriate surgical and/or medical management, and require on-going evaluation to monitor for recurrence and metastatic disease. This includes: Primary use in patients with inability to raise an endogenous TSH level ( 25 mu/l) with thyroid hormone withdrawal. Primary use in cases of documented morbidity in patients for whom severe hypothyroidism could be life threatening, such as unstable angina, recent myocardial infarction, class III to IV congestive heart failure, or uncontrolled psychiatric illness. Secondary use in patients with previous thyroid hormone withdrawal resulting in a documented life-threatening event. Medications for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) Coverage of the following medications for the treatment of COPD will be provided to patients who meet established clinical criteria and who are eligible for coverage through the Family Health Benefit, Financial Assistance, Seniors, and Nursing Home Programs. A completed Special Authorization form must be received by the Drug Programs office before coverage will be considered. Patients will be required to pay the normal prescription copays for these programs. Formoterol Foradil - 12 ug per dose Powder Capsules Oxeze Turbuhaler - 6 ug and 12 ug per dose Powder for Inhalation Formoterol & Budesonide (Symbicort Turbuhaler) 6 ug & 100 ug and 6 ug & 200 ug per dose Powder for Inhalation Salmeterol Servent - 50 ug per dose Aerosol Powder Disk Serevent Diskus 50 ug per dose Powder for Inhalation Salmeterol & Fluticasone Advair 25 ug & 125 ug and 25 ug & 250 ug per dose Inhaler Aerosol Advair Diskus 50 ug & 100 ug, 50 ug & 250 ug, and 50 ug & 500 ug per dose Powder for Inhalation Tiotropium (Spiriva) 18 ug per dose Inhalation Powder Capsule The criteria for coverage of all of the new COPD medications are as follows: 1. For the treatment of mild, moderate, and severe chronic obstructive pulmonary disease (COPD) (i.e. MRC score 2, see below) in patients who continue to be symptomatic after a 3 month trial of ipratropium at a dose of 12 puffs/day and appropriate use of short-acting beta -agonists. 2. For the treatment of moderate to severe chronic obstructive pulmonary disease (COPD) (i.e. MRC score 3 to 5, see below) without a trial of short-acting agents (e.g. ipratropium and beta2-agonists) where spirometry shows moderate to severe airflow obstruction (i.e. FEV1 < 60% predicted and low FEV1/FVC <0.7). A copy of the spirometry report must accompany the Special Authorization. 2 Note: Note: The drug programs will not pay for concurrent use of Tiotropium and Ipratropium. Concurrent use of Tiotropium and Long Acting Beta2-Agonists or Long Acting Beta2-Agonists/Inhaled Corticosteroids will only be considered in patients where FEV1 < 60% predicted and FEV1/FVC <0.7. PEI Drug Programs Update - Issue Page 3
4 Medical Research Council Dyspnea Scale Grade Degree of breathlessness related to activities Not troubled by breathlessness except on strenuous exercise Short of breath when hurrying or walking up a slight hill Walks slower than contemporaries on level ground because of breathlessness, or has to stop for breath when walking at own pace Stops for breath after walking about 100m or after a few minutes on level ground Too breathless to leave the house, or breathless when dressing or undressing Reference: Fletcher C.M. et al The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Brit. Med. J. 2: Medications for the Treatment of Osteoporosis The Special Authorization criteria for the coverage of the Etidronate and Calcium Carbonate (Didrocal and generics) through the Family Health Benefits, Financial Assistance, Nursing Home, and Seniors Programs have been removed. A Special Authorization is no longer needed for the coverage of these products. Patients will be required to pay the normal prescription copays for these programs. Etidronate Disodium & Calcium Carbonate (Didrocal & generics) 400 mg & 1250 mg Tablets (Package) Coverage of Alendronate, Risedronate, and Calcitonin for the treatment of osteoporosis has been approved for patients who meet established clinical criteria and who are eligible for coverage through the Family Health Benefit, Financial Assistance, Nursing Home, and Seniors Programs. A completed Special Authorization form must be received by the Drug Programs office before coverage will be considered. Patients will be required to pay the normal prescription copays for these programs. Alendronate (Fosamax & generics) 10 mg and 70 mg Tablets 1. For the treatment of osteoporosis in patients with a documented fragility fracture. 2. For use in patients without documented fracture but with a high 10-year fracture risk (see fracture risk tables, see below). A copy of the bone density report, including the T-score, supporting the diagnosis must accompany the Special Authorization. 3. For prophylaxis of corticosteroid induced osteoporosis in patients who will be or have been on systemic corticosteroid therapy for 3 months. Risedronate (Actonel) 5 mg and 35 mg Tablets 1. For the treatment of osteoporosis in patients with a documented fragility fracture. 2. For use in patients without documented fracture but with a high 10-year fracture risk (see fracture risk tables, see below). A copy of the bone density report, including the T-score, supporting the diagnosis must accompany the Special Authorization. 3. For prophylaxis of corticosteroid induced osteoporosis in patients who will be or have been on systemic corticosteroid therapy for 3 months. PEI Drug Programs Update - Issue Page 4
5 Calcitonin (Salmon Synthetic) (Miacalcin & generics) 200 iu per dose Nasal Spray 1. For the treatment of osteoporosis in patients with a documented fragility fracture and when etidronate, alendronate and risedronate are not tolerated or are contraindicated. 2. For use in patients without documented fracture but with a high 10-year fracture risk (see fracture risk tables, see below) and when etidronate, alendronate and risedronate are not tolerated or are contraindicated. A copy of the bone density report, including the T-score, supporting the diagnosis must accompany the Special Authorization. 3. For the short term (up to 3 months) treatment of pain associated with osteoporotic fragility fractures, bone metastases, or pathological fractures. A copy of the radiological or specialist report supporting the diagnosis must accompany the Special Authorization. Fracture Risk Tables Age (years) Low Risk <10% Women 10-Year Risk Moderate Risk 10% - 20% Lowest T-Score Lumbar spine, total hip, femoral neck, trochanter High Risk > 20% 50 > to -3.9 < -3/9 55 > to -3.4 < > to -3.0 < > to -2.6 < > to -2.2 < > to -2.1 < > to -2.0 < > to -2.2 < -2.2 Age (years) Low Risk <10% Men 10-Year Risk Moderate Risk 10% - 20% Lowest T-Score Lumbar spine, total hip, femoral neck, trochanter High Risk > 20% 50 > -3.4 < = > -3.1 < = > -3.0 < = > -2.7 < = > to -3.9 < > to -3.2 < > to -3.0 < > to -3.3 < -3.3 Reference: Siminoski K. et al Recommendations for bone mineral density reporting in Canada. Can. Assoc. Radiol. J. 56: PEI Drug Programs Update - Issue Page 5
6 Medications for the Treatment of Paget s Disease Coverage of the following medications for the treatment of Paget s Disease have been approved for patients who meet established clinical criteria and who are eligible for coverage through the Family Health Benefit, Financial Assistance, Nursing Home, and Seniors Programs. A completed Special Authorization form must be received by the Drug Programs office before coverage will be considered. Patients will be required to pay the normal prescription copays for these programs. Alendronate (Fosamax & generics) 40 mg Tablets For the treatment of Paget s disease of bone for a maximum 6 month period. A copy of the radiological or specialist report supporting the diagnosis must accompany the Special Authorization. Risedronate (Actonel) 30 mg Tablets For the treatment of Paget s disease of bone for a maximum 2 month period. One additional 2 month course of treatment may be considered after a drug holiday of at least 60 days. A copy of the radiological or specialist report supporting the diagnosis must accompany the Special Authorization. Zoledronic Acid (Aclasta) 5 mg/100 ml Injection Solution For the treatment of Paget s disease of the bone. A copy of the radiological or specialist report supporting the diagnosis must accompany the Special Authorization. HIV/AIDS Medications The following medications have been approved for the coverage through the HIV/AIDS Program. All medications for the HIV/AIDS Program must be filled at the Provincial Pharmacy located in Charlottetown. Dronabinol (Marinol) 2.5 mg and 5 mg Capsules For the treatment of acquired immune deficiency syndrome (AIDS)-related anorexia associated with weight loss. Efavirenz & Embricitabine & Tenofovir (Atripla) Tablets Etravirine (Intelence) 100 mg Tablets Maravirox (Celsentri) 150 mg and 300 mg Tablets Raltegravir (Isentress) 400 mg Tablets The Special Authorization criteria for coverage of Tenofovir and Tenofovir/Embricitabine have been removed. An Special Authorization is no longer needed for the coverage of these products. However, prescription for these medications must be filled at the Provincial Pharmacy. Tenofovir (Viread) 300 mg Tablets Tenofovir & Embricitabine (Truvada) 300 mg & 200 mg Tablets For More Information For more information on PEI Drug Programs or any medications covered by the programs, please contact the Drug Programs office at: Phone: in the Charlottetown area toll free in PEI Fax: PEI Drug Programs Update - Issue Page 6
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationNBPDP Formulary Update
Bulletin #878 December 19, 2013 NBPDP Formulary Update This update to the New Brunswick Prescription Drug Program (NBPDP) Formulary is effective December 19, 2013. Included in this bulletin: Regular Benefit
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationNB Drug Plans Formulary Update
Bulletin # 963 December 15, 2017 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective December 15, 2017. Included in this bulletin: Special Authorization Benefit
More informationTHE COPD PRESCRIBING TOOL
THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationNexavar. Nexavar (sorafenib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.60 Section: Prescription Drugs Effective Date: July 1,2017 Subject: Nexavar Page: 1 of 5 Last Review
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationThree triggers that suggest that patients could benefit from a hospice palliative care approach
Why is it important to identify people nearing the end of life? About 1% of the population dies each year. Although some deaths are unexpected, many more in fact can be predicted. This is inherently difficult,
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1 of 6 Last Review Date: March 16, 2018 Tasigna Description Tasigna (nilotinib)
More informationTRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationSutent. Sutent (sunitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.95 Subject: Sutent Page: 1 of 5 Last Review Date: September 15, 2017 Sutent Description Sutent (sunitinib)
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1of 5 Last Review Date: September 15, 2017 Tasigna Description Tasigna (nilotinib)
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More informationCOPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes
COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationNBPDP FORMULARY UPDATE
Bulletin #864 June 20, 2013 NBPDP FORMULARY UPDATE This update to the New Brunswick Prescription Drug Program (NBPDP) Formulary is effective June 20, 2013. Included in this bulletin: Regular Benefit Additions
More informationNB Drug Plans Formulary Update
Bulletin #971 March 20, 2018 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective March 20, 2018. Included in this bulletin: Regular Benefit Additions Changes
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationSTRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationTarceva. Tarceva (erlotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.82 Subject: Tarceva Page: 1 of 5 Last Review Date: June 22, 2018 Tarceva Description Tarceva (erlotinib)
More informationArea Drug and Therapeutics Committee Prescribing Supplement No 20 December 2007
Area Drug and Therapeutics Committee Prescribing Supplement No 20 In this issue Drugs currently being considered by SMC advice due on 14 January 2008. Lanarkshire Joint Formulary 2 nd edition November
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More informationLong Term Care Formulary RS -29
RESTRICTED USE Asthma/COPD Management 1 of 6 PROTOCOL: Asthma Glossary of Medication Acronyms: SABA: short-acting beta agonist (e.g. salbutamol) SABD: short-acting bronchodilator (e.g. ipratropium or SABA)
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 HIROBRIZ BREEZHALER 150 micrograms, inhalation powder, hard capsules B/10 with inhaler (CIP code:
More informationBosulif. Bosulif (bosutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.22 Section: Prescription Drugs Effective Date: April 1,2018 Subject: Bosulif Page: 1 of 5 Last Review
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 1067-7 Program Prior Authorization/Notification Medication Nexavar (sorafenib tosylate) P&T Approval Date 8/2008, 6/2009, 6/2010,
More informationClinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18
Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationBONIVA (ibandronate sodium)
BONIVA (ibandronate sodium) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Sprycel) Reference Number: CP.PHAR.72 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationNew Exception Status Benefits
MARCH 2015 Nova Scotia Formulary Updates New xception Status Benefits Harvoni (ledipasvir/sofosbuvir) Sovaldi (sofosbuvir) BRO LLIPTA (fluticasone furoate/vilanterol (as trifenatate)) Onglyza (saxagliptin)
More informationOsteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011
Osteoporosis - New Guidelines Michelle Glass B.Sc. (Pharm) June 15, 2011 Outline What is Osteoporosis? Who is at risk? What treatments are available? Role of the Pharmacy technician Definition of Osteoporosis
More informationSutent. Sutent (sunitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.95 Subject: Sutent Page: 1 of 6 Last Review Date: March 16, 2018 Sutent Description Sutent (sunitinib)
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationMULTICARE Health System Care of the Adult Chronic Obstructive Pulmonary Disease (COPD) Patient
Clinical Guideline Ver. 2.0 MULTICARE Health System Care of the Adult Chronic Obstructive Pulmonary Disease (COPD) Patient Target Audience: The target audience for this clinical guideline is all MHS providers
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tasigna) Reference Number: CP.PHAR.76 Effective Date: 09.01.11 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationTrends in Glucocorticoid-Induced Osteoporosis Management Among Seniors in Ontario,
Trends in Glucocorticoid-Induced Osteoporosis Management Among Seniors in Ontario, 1996-2012 Jordan M Albaum 1, Linda E Lévesque 2, Andrea S Gershon 3, Yan Yun Liu 1, Suzanne M Cadarette 1 1 Leslie Dan
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR
More informationThis Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. INJECTABLE OSTEOPOSIS AGENTS SUBJECT Pharmacologic Agents: Bisphosphonates: Boniva IV (ibandronate) Reclast (zoledronic
More informationDrug Class Monograph
Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationNew Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved.
Drug Review and The following tables list the Agenda items as well as the that are scheduled to be presented and reviewed at the March 15, 2018 meeting of the Pharmacy and Therapeutics Advisory Committee.
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationMedical Directive. Activation Date: April 24, 2013 Review due by: December 1, Medical Director: Date: December 1, 2017
Medical Directive Pre and Post Bronchodilator Spirometry Testing and Treatment Initiation Assigned Number: Activation Date: April 24, 2013 Review due by: December 1, 2019 23 Approval Signature & Date Medical
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 25 May 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 25 May 2011 Examination of the file for the proprietary medicinal product included for a period of 5 years by the
More informationNB Drug Plans Formulary Update
Bulletin # 967 February 12, 2018 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective February 12, 2018. Included in this bulletin: Regular Benefit Additions
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Fluticasone/Salmeterol (Advair Diskus, Advair HFA) Reference Number: CP.PMN.31 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan See Important Reminder
More informationTYMLOS (abaloparatide)
TYMLOS (abaloparatide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1101-7 Program Prior Authorization/Notification Medication Sutent (sunitinib malate) P&T Approval Date 8/2008, 6/2009, 6/2010,
More informationPresented by UIC College of Nursing
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long-acting inhalers and emergency use inhalers.
More informationChronic Obstructive Pulmonary Disease 1/18/2018
Presented by UIC College of Nursing Describe COPD. Identify red flags for a COPD exacerbation. Identify COPD triggers or risk factors. Differentiate between long acting inhalers and emergency use inhalers.
More informationResearch in Real Life Evaluation of patients with COPD and CKD who would benefit from aclidinium bromide treatment. Version Date: 15 th October 2013
Research in Real Life Evaluation of patients with COPD and CKD who would benefit from aclidinium bromide treatment. Version Date: 15 th October 2013 Draft protocol Characterising patient groups with chronic
More informationProposal on subsidy changes for some respiratory inhalation products and access restrictions to combination inhalers.
30 August 2011 Proposal on changes for some respiratory products and access restrictions to combination inhalers. As notified on 16 June 2011, PHARMAC has been considering options for managing the funding
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationTARCEVA (erlotinib) oral tablet
TARCEVA (erlotinib) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationCOPD/ Asthma. Dr Heather Lewis Honorary Clinical Lecturer
COPD/ Asthma Dr Heather Lewis Honorary Clinical Lecturer Objectives To understand the pathogenesis of asthma/ COPD To recognise the clinical features of asthma/ COPD To know how to diagnose asthma/ COPD
More informationSelf-Management Plan for COPD
Self-Management Plan for COPD This is your personal management plan. The aim of this plan is to help you have better control of your chronic obstructive pulmonary disease (COPD). It will enable you to
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Seebri Neohaler) Reference Number: CP.CPA.150 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More informationAdded, Removed or Changed. Date of Change. No Change
One mission: you s September 7, 2017 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for your
More informationBENEFIT CHANGES TO NBPDP
Bulletin #789 June 15, 2010 BENEFIT CHANGES TO NBPDP This update to the New Brunswick Prescription Drug Program (NBPDP) Formulary is effective June 15, 2010. Included in this bulletin: Regular Benefit
More informationBetter Living with Obstructive Pulmonary Disease A Patient Guide
Better Living with Obstructive Pulmonary Disease A Patient Guide Second Edition November 2012 Queensland Health a Better Living with Chronic Obstructive Pulmonary Disease A Patient Guide is a joint project
More informationMedications Affecting The Respiratory System
Medications Affecting The Respiratory System Overview Asthma is a chronic inflammatory disorder of the airways. It is an intermittent and reversible airflow obstruction that affects the bronchioles. The
More informationFORTEO (teriparatide) INJECTION
FORTEO (teriparatide) INJECTION Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Medical Benefit Effective: 6/15/18 Pharmacy- Formulary 1 x Next Review: 6/19 Pharmacy- Formulary 2 x Date of Origin: 4/99 Antiemetic Agents: Zofran /ODT (ondansetron/ondansetron
More informationKentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations
Kentucky Department for Medicaid Services Pharmacy and March 15, 2018 The following chart provides a summary of the recommendations that were made by the Pharmacy and Therapeutics (P&T) Advisory Committee
More informationBisphosphonate Step Therapy Criteria
ϯ ϯ ϯ A Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association Bisphosphonate Step Therapy Criteria Program may
More informationNew 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS
New 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS Wednesday, December 1, 2010 1:00 p.m. to 2:00 p.m. ET 1. I m 55 years old. I ve been taking Fosavance
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION (FLUTICASONE FUROATE/VILANTEROL) (Breo Ellipta GlaxoSmithKline) Indication: Chronic Obstructive Pulmonary Disease Recommendation: The Canadian Drug Expert Committee (CDEC) recommends
More informationNews on Evidence-Based Care Fourth Quarter 2013 Volume 5 Issue 4
SPECIAL EDITION: COPD CME AVAILABLE! News on Evidence-Based Care Fourth Quarter 2013 Volume 5 Issue 4 Update on Chronic Obstructive Lung Disease (COPD) 2013 During 2013, the Institute for Evidence-Based
More informationStivarga. Stivarga (regorafenib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.26 Subject: Stivarga Page: 1 of 5 Last Review Date: September 15, 2017 Stivarga Description Stivarga
More informationClinical Policy: Nilotinib (Tasigna) Reference Number: CP.CPA.162 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Tasigna) Reference Number: CP.CPA.162 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Bosulif) Reference Number: CP.PHAR.105 Effective Date: 10.01.12 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationNCCP Chemotherapy Protocol. Bosutinib Monotherapy
Bosutinib Monotherapy INDICATIONS FOR USE: INDICATION Treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous
More informationNational Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial design:
Open clinical uro-oncology trials in Canada Eric Winquist, MD, Mary J. Mackenzie, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A PHASE III STUDY OF IRESSA
More informationSelf-Management Plan for COPD
Self-Management Plan for COPD This is your personal management plan. The aim of this plan is to help you have better control of your chronic obstructive pulmonary disease (COPD). It will enable you to
More informationSelf-Management Plan for COPD
Self-Management Plan for COPD This is your personal management plan. Bring it with you every time you see a nurse or doctor about your COPD The aim of this plan is to help you have better control of your
More informationAzacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded
Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from
More informationClinical Policy: Sorafenib (Nexavar) Reference Number: CP.PHAR.69 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Nexavar) Reference Number: CP.PHAR.69 Effective Date: 07.01.11 Last Review Date: 05.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for
More informationCABOMETYX (cabozantinib) oral tablet
CABOMETYX (cabozantinib) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationPage 1
Osteoporosis Osteoporosis is a condition characterised by weakened bones that fracture easily. After menopause many women are at risk of developing osteoporosis. Peak bone mass is usually reached during
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationArea Drug and Therapeutics Committee Prescribing Supplement No 16 May 2007
Area Drug and Therapeutics Committee Prescribing Supplement No 16 In this issue Drugs currently being considered by the SMC advice due on 11 June 07. Correction to the last edition (No 15) of the prescribing
More informationIclusig. Iclusig (ponatinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.30 Subject: Iclusig Page: 1of 6 Last Review Date: June 22, 2018 Iclusig Description Iclusig (ponatinib)
More informationChronic Obstructive Pulmonary Disease Guidelines and updates
Chronic Obstructive Pulmonary Disease Guidelines and updates October 20, 2018 Saratoga Springs, NY COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United
More informationBisphosphonates. Making intelligent drug choices
Making intelligent drug choices Bisphosphonates are a first choice for treating osteoporosis, according to Kedrin E. Van Steenwyk, DO, an obstetrician/gynecologist at Sycamore Women s Center, Miamisburg,
More informationS H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women
S H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women Introduction Indication: Denosumab (Prolia ) is recommended in NICE TA204
More informationClinical Policy: Pazopanib (Votrient) Reference Number: ERX.SPA.139 Effective Date:
Clinical Policy: (Votrient) Reference Number: ERX.SPA.139 Effective Date: 03.01.14 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More information